Clinical trials: Liver Inflammation
Hepatocellular Carcinoma, Hepatocellular Cancer
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis
- Trial name
- NCT05064553
- Testing
- Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
- Where
- 76 sites in United States
- Volunteers
- 2,990 people
- Sponsor
- Exact Sciences Corporation
Hepatitis B, Polio
Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants
The purpose of the study is to provide immunogenicity and safety data of the investigational hexavalent vaccine when it is given concomitantly (the same day at separate injection sites) with Prevnar, according to the 2-4-6 month…
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00401531
- Testing
- DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines, DTaP-HB-IPV and Pneumococcal polysaccharide vaccines
- Where
- 2 sites in Thailand
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis A
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
Three dose primary vaccination study of reactogenicity and immunogenicity in healthy infants between 6-12 weeks of age at the time of the first vaccination against Streptococcus pneumoniae.
- Trial name
- NCT00338351
- Testing
- Pneumococcal (vaccine)
- Where
- Chile
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C Infection, Chronic Hepatitis C
An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine
The purpose of this study is to evaluate the safety and efficacy of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir)…
- Trial name
- NCT01911845
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV)
- Volunteers
- 38 people
- Sponsor
- AbbVie
Hepatitis C Virus Infection
Expanded Access to Glecaprevir/ Pibrentasvir
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to glecaprevir/ pibrentasvir prior to approval by the local regulatory agency.
- Trial name
- NCT03123965
- Testing
- glecaprevir, pibrentasvir
- Where
- Slovenia
- Sponsor
- AbbVie
Hepatitis B
Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children
This study will evaluate the persistence of immunity to hepatitis B 10 to 11 years after vaccination with Infanrix hexa™ or Engerix™-B and also the ability to mount an immune response to the challenge dose of Engerix™-B.
- Trial name
- NCT01138098
- Testing
- Engerix™-B
- Where
- 11 sites in Slovakia
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C
Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus
The purpose of this study is to evaluate the safety, immunogenicity, and antiviral effects of multiple intravenous doses of ANZ-521 in patients with chronic Hepatitis C virus.
- Trial name
- NCT00800007
- Testing
- ANZ-521
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Anza Therapeutics, Inc.
Chronic Hepatitis B
Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients
This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with anti viral therapy and vaccine in patients with Hepatitis B chronic infection.
- Trial name
- CONVERT (NCT01027065)
- Testing
- CYT107+GenHevac+entecavir or tenofovir, CYT107+ entecavir or tenofovir
- Where
- 8 sites in France, Italy
- Volunteers
- 24 people
- Sponsor
- Cytheris SA
Haemophilus Influenzae Type b, Tetanus
Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers
The purpose of the study is to assess the immunogenicity and safety of three formulations of GSK Biologicals' GSK2036874A vaccine compared to Zilbrix™/Hib and Poliorix™ vaccines administered concomitantly, when administered as a…
- Conditions
- Haemophilus Influenzae Type b, Tetanus, Hepatitis B, Whole Cell Pertussis
- Trial name
- NCT01106092
- Testing
- GSK2036874A vaccine, Zilbrix™/Hib vaccine, Poliorix™
- Where
- Philippines
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B Virus Infection
A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients
This is a randomized, double-blind, placebo-controlled Phase I dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of multiple ascending doses (120 mg, 240 mg, 480 mg SC, QW×5) of…
- Trial name
- NCT07515209
- Testing
- HH-006, 0.9% normal saline
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Huahui Health
Hepatitis C Virus
Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus
The purpose of this study is to assess the safety and efficacy of daclatasvir and simeprevir with and without ribavirin for genotype 1 chronic hepatitis C virus infection in patients who are treatment-naive or null responders to…
- Trial name
- NCT01628692
- Testing
- Daclatasvir, Simeprevir, Ribavirin
- Where
- 26 sites in United States, Argentina and 4 more
- Volunteers
- 230 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis B
Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
The purpose of this study was to determine the safety and antiviral hepatitis B virus (HBV) activity of ACH126, 433 in the treatment of adults with lamivudine-resistant chronic hepatitis B.
- Trial name
- NCT00040144
- Testing
- ACH126, 433
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 85 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hepatitis C Virus (HCV)
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
A Phase 3b, single arm, open-label, multicenter study in treatment naïve adults with chronic HCV infection and compensated cirrhosis to assess the safety of 8 weeks of treatment with glecaprevir/pibrentasvir and to demonstrate…
- Trial name
- EXPEDITION-8 (NCT03089944)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 113 sites in United States, Bulgaria and 17 more
- Volunteers
- 343 people
- Sponsor
- AbbVie
Hepatitis C
A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects
This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus concomitant Rebetol vs.
- Trial name
- NCT00367887
- Testing
- Peg-Intron, REBETOL, HCV 796
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 246 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hepatitis C
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
To assess the safety, tolerability and pharmacokinetics of the ABT-072 tablet formulation administered as a single dose and then administered as multiple doses for 7 days.
- Trial name
- NCT00982826
- Testing
- ABT-072
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Abbott
Chronic Hepatitis B
Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States
The objective of this study is to provide open label emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for an additional 5 years (240 weeks) to adults completing study GS-US-203-0107.
- Trial name
- NCT00936715
- Testing
- FTC/TDF
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection
The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination with peginterferon alfa-2b and ribavirin in chronic genotype 1 hepatitis C virus (HCV)-infected participants who are treatment-naive or…
- Trial name
- NCT01366638
- Testing
- TMC435, Peginterferon alfa-2b (pegIFN alfa-2b), Ribavirin (RBV)
- Where
- 11 sites in Japan
- Volunteers
- 79 people
- Sponsor
- Janssen Pharmaceutical K.K.
Immunogenicity
Protectivity and Safety Following Recombinant Hepatitis B Vaccine
Protectivity and Safety Following Recombinant Hepatitis B Vaccine with different source of Hepatitis B bulk compared to Hepatitis B (Bio Farma) vaccine in Indonesian Population
- Trial name
- NCT03919578
- Testing
- Recombinant Hepatitis B vaccine, Recombinant Hepatitis B (Bio Farma)
- Where
- Indonesia
- Volunteers
- 536 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Hepatitis B
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2803 in Healthy Subjects
This study is an open-label, randomized, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of DA-2803 in healthy subjects
- Trial name
- NCT04906109
- Testing
- Vemlidy Tab, DA-2803 Tab
- Where
- South Korea
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Poliomyelitis, Tetanus
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
This study will evaluate the immunogenicity of the co-administration of different combinations of DTPa, IPV, hepatitis B, Hib and Men C vaccines during the first year of life.
- Conditions
- Poliomyelitis, Tetanus, Acellular Pertussis, Hepatitis B
- Trial name
- NCT00352963
- Testing
- Study vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec
- Where
- 22 sites in Spain
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.